Robert Horlick, Ph.D. is Vice President of Molecular Cell Biology. Rob has more than 30 years of experience in molecular biology, molecular pharmacology and antibody drug discovery and development. Prior to joining Lassen, he was a co-founding scientist of AnaptysBio and head of Molecular Biology. He co-developed the company’s antibody discovery and somatic hypermutation platform and led the etokimab (anti-IL-33 antibody) program from inception to preclinical nomination. Rob spent 10 years at DuPont, where he focused on drug discovery for inflammatory and CNS diseases. He subsequently worked at Pharmacopeia Inc., Millennium Pharmaceuticals and X-Ceptor Therapeutics, leading small molecule drug discovery programs in inflammatory and metabolic diseases. He is an inventor on 14 issued US patents and has authored over 30 peer-reviewed articles. Rob received his Ph.D. in Biology from Johns Hopkins University, working at NIH as part of the NIH-Hopkins graduate program. He also holds a B.S. in Microbiology from the University of Maryland.